Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Pharmacokinetics and Pharmacodynamics"
DOI: 10.1007/s10928-019-09619-6
Abstract: Danvatirsen is a Generation 2.5 antisense oligonucleotide under clinical development. Population PK modelling was conducted using data from 3 available danvatirsen Phase I/II studies in oncology patients to investigate the impact of flat dosing on… read more here.
Keywords: flat dosing; analysis; population pharmacokinetic; model ... See more keywords
Different dosing strategies of pembrolizumab in the treatment of NSCLC: A real-world retrospective observational study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e23264
Abstract: e23264 Background: Immune checkpoint inhibitors lack a dose-response relationship, allowing optimisation of dosing strategies that may reduce drug use. Pembrolizumab received its initial regulatory approval for the treatment of non-small cell lung cancer (NSCLC) at… read more here.
Keywords: treatment; pembrolizumab; use; flat dosing ... See more keywords